Pazopanib Hcl
Brand name: Votrient
Rank #483 of 500 drugs by total cost
$14.5M
Total Cost
1,156
Total Claims
$14.5M
Total Cost
81
Prescribers
$13K
Cost per Claim
0
Beneficiaries
1,159
30-Day Fills
$179K
Avg Cost/Provider
14
Avg Claims/Provider
About Pazopanib Hcl
Pazopanib Hcl (sold as Votrient) was prescribed 1,156 times by 81 Medicare Part D providers in 2023, costing the program $14.5M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 480 | Mometasone Furoate (Mometasone Furoate) | $14.7M | 266,966 |
| 481 | Lorlatinib (Lorbrena) | $14.7M | 720 |
| 482 | Rasagiline Mesylate (Rasagiline Mesylate) | $14.5M | 47,985 |
| 483 | Pazopanib Hcl (Votrient) | $14.5M | 1,156 |
| 484 | Exemestane (Exemestane) | $14.5M | 66,285 |
| 485 | Dihydroergotamine Mesylate (Dihydroergotamine Mesylate) | $14.4M | 6,855 |
| 486 | Clotrimazole/Betamethasone Dip (Clotrimazole-Betamethasone) | $14.4M | 503,015 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology